Jam
-
Coveo AI to Enhance DocuSign Customer Support
Coveo, an AI-Relevance leader, announced Docusign selected its AI-Search and Relevance Generative Answering to enhance customer support. Docusign aims to improve self-service, optimize agent workflows, and ensure consistent responses, reducing time spent finding information. Coveo’s platform offers scalability, security, and actionable intelligence, promising increased efficiency and improved experiences. Coveo’s AI aggregates content, amplifies case deflection, and cuts down answer-seeking time, driving operational efficiency and personalized support.
-
Luxxfolio Announces Corporate Update and Litecoin Treasury Expansion
LUXXFOLIO Holdings (CSE: LUXX) increased its Litecoin treasury to 20,084 LTC, a 151.6% Litecoin-per-share yield. The company closed a $2.5 million financing and deployed 841 cbLTC into decentralized liquidity protocols for yield generation. LUXXFOLIO is advancing Litecoin infrastructure development and remains debt-free. Geoff Balderson replaced Geoff McCord as CFO and Director. They are focusing on stablecoin payments and yield.
-
Share Buyback Details: July 10 – July 16, 2025
Wolters Kluwer (WTKWY) repurchased 196,897 shares between July 10-16, 2025, at an average price of €139.16, totaling €27.4 million. This is part of their €1 billion share buyback program for 2025. To date, they’ve repurchased 3,885,856 shares for €590.6 million, averaging €151.99 per share. They’re using third parties to execute €350 million of the buybacks between May 8 and July 28, 2025 for capital reduction.
-
Genflow Announces Grant Progress
Genflow Biosciences (GENFF) secured a €4 million non-dilutive grant from Belgium’s Wallonia Region to advance GF-1002, its gene therapy candidate for Metabolic Associated Steatohepatitis (MASH). The grant covers a three-year development program aligned with Genflow’s clinical roadmap. While initial disbursement awaits administrative procedures, the GF-1002 program continues without interruption. Genflow highlights that all project-related expenses incurred in 2025 will be eligible under the grant’s terms.
-
Correction Notice for Ridgeline Minerals Annual General Meeting
Ridgeline Minerals (RDGMF) has corrected a typographical error in its upcoming Annual General Meeting (AGM) materials, clarifying the record date as July 3, 2025. The AGM is still scheduled for August 12, 2025. Amended materials are available on SEDAR+ and the company website. Ridgeline Minerals focuses on exploration across seven projects in Nevada, holding both wholly-owned assets and strategic partnerships.
-
First Andes Silver Completes First Tranche of Private Placement
First Andes Silver (TSXV: FAS, OTC: MSLVF) completed the first tranche of a non-brokered private placement, raising $1.017 million CAD. They issued 10,170,000 units at $0.10 CAD each, including warrants exercisable at $0.15 CAD. Proceeds will fund drilling at the Santas Gloria silver property and working capital. The company paid finder’s fees and issued warrants. Securities have a four-month resale restriction. A second tranche is expected to close soon, pending TSX Venture Exchange approval.
-
Additional Regional Soil Sampling Programs Completed
This document describes a client-side function, likely named `parseRating`, designed for processing and interpreting rating data. The function aims to extract and format numerical or categorical rating values from an input source, possibly a web page section related to product reviews or customer feedback. The formatted rating can then be displayed dynamically or used for further client-side computations. The exact implementation details and input/output formats are not explicitly stated but are implied by the function’s purpose.
-
NKGen Biotech Secures Funding to Restore Compliance and Maintain Nasdaq Listing
NKGen Biotech (NKGN) secured $2M from a Japanese investor to regain compliance after its parent company’s bankruptcy. Shares move to OTC Expert Market temporarily before uplisting to OTCQB and eventually Nasdaq/NYSE American. The funding supports the development of troculeucel, an NK cell therapy for neurodegenerative diseases moving forward in Phase 2 trials. NKGen also plans to acquire a majority stake in NKMax, consolidating key IP rights across Asia.
-
LendingTree to Announce Second Quarter 2025 Earnings on July 31, 2025
LendingTree, Inc. (NASDAQ: TREE) will release its Q2 2025 earnings on July 31, 2025, after market close. A shareholder letter will be available on its investor relations website. A conference call will be held at 5:00 p.m. ET, featuring CEO Doug Lebda, to discuss financial highlights and future strategies. A live webcast and replay will be accessible on the company’s website. LendingTree operates a large online financial platform connecting consumers with financial partners for various financial products.
-
Netcapital Announces $5.9M Direct Offering Priced At-Market
Netcapital (NCPL) announced a registered direct offering of 641,712 shares at $4.675 per share, aiming for $3 million in gross proceeds. A concurrent private placement offers unregistered short-term warrants for up to 641,712 shares at $4.55 each, potentially adding $2.9 million if fully exercised. Slated to close around July 17, 2025, with H.C. Wainwright & Co. as placement agent, the proceeds will repay promissory notes and fund working capital. The offering involves shareholder dilution with potential for further dilution.